paroxysmal nocturnal hemoglobinuria

And so there, there could be some others that we want to talk about in the future, but there's five on here.

The big guys are on here at Cargill, G3, JRI, Bungie, PNH.

They're all on here.

Um, Patterson, I didn't get the Patterson numbers on here yet.

Now I need to thank Sarah with trigger grain cause she, she's compiling this information all the time.

And, but anyways, um, you need to be armed with that information because what happens if you have a contract at G3? You know, like us, right? Like contract at G3, like...

but yet PNH is right there with a five cent discount, but yet I've sold it over to G3.

Like you need to have this information available to you because there's no, it's not like they look out into the sea and they're like, Oh, it rained over here now.

[laughs] And you wanna check TP53 first, and note that it now has a role in ESA-refractory non-deletion 5q disease And then finally, for hypoplastic hypocellular MDS, you are gonna treat those like aplastic anemia with immunosuppression, with ATG and cyclosporine and a thrombopag.

And it's best in patients under the age of 60 with less than 5% blasts and if they have PNH clone that is positive.

And then IDH mutated lower risk after failure of ESAs, you can also consider the IDH1 inhibitor ivosidenib or enasidenib, which is a IDH2 inhibitor.

Definitely.